

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
156th Meeting of the Vaccines and Related Biological Products Advisory Committee
(VRBPAC)**

**FDA White Oak Campus, Building 31, Great Room Salon B & C
Silver Spring, MD**

March 22, 2019

AGENDA

Meeting Link:

<https://collaboration.fda.gov/vrbpac032019/>

March 22, 2019

Topic: H3N2 Strain Selection for the Influenza Virus Vaccines for the 2019 – 2020 Influenza Season

Note: Committee members are participating via teleconference

Time	Presentation/Presenter
8:30 AM	<p><u>Opening Remarks: Call to Order, Introduction of Committee</u> Hana El Sahly, M.D. Acting Chair, VRBPAC</p> <p><u>Administrative Announcements, Conflict of Interest Statement</u> Serina Hunter-Thomas, M.S.A., R.N. Designated Federal Officer, VRBPAC CBER, FDA</p>
8:45 AM	<p><u>Introduction and Presentation of Questions</u> Jerry Weir, Ph.D. Director Division of Viral Products (DVP) Office of Vaccines Research and Review (OVRP) CBER, FDA</p>
9:15 AM	<p><u>World Surveillance/Virus Characterization</u> Jacqueline Katz, Ph.D. Deputy Director, Influenza Division and Director, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention (CDC)</p>
10:15 AM	<p>Break (15 minutes)</p>

10:30 AM	Open Public Hearing (60 minutes)
11:30 AM	Committee Discussion, Recommendations, and Vote
1:30 PM	Adjourn Meeting